The World Health Organization had endorsed Xpert ® MTB/RIF (Xpert) as the initial diagnostic for multidrugresistant tuberculosis (TB) or TB suspects co-infected with the human immunodeficiency virus. We investigated an unexpected case of rifampicin (RMP) resistance on Xpert using repeat Xpert, smear microscopy, MTBDRplus assay, culture, drug susceptibility testing, spoligotyping and rpoB gene sequencing. A false-positive result was most likely, given the wild type rpoB gene sequence and exclusion of both mixed infection and mixture of drug-susceptible and drug-resistant populations. When decentralising Xpert, test performance characteristics need to be understood by health care workers and methods of confirmation of RMP resistance need to be accessible.
MULTIDRUG-RESISTANT tuberculosis (MDR-TB)
threatens global TB control. The World Health Organization (WHO) has endorsed the Xpert ® MTB/RIF test (Xpert; Cepheid, Inc, Sunnyvale, CA, USA) as the initial diagnostic for those at risk of MDR-TB or human immunode ciency virus (HIV) associated TB. 1 Rapid diagnosis of rifampicin (RMP) resistance could reduce the morbidity, mortality and transmission of drug-resistant TB.
The rst large clinical Xpert validation study reported 100% speci city for the detection of RMP resistance after resolution of discordances by rpoB genotyping. 2 In a subsequent multicentre study, the speci city for RMP resistance was found to be lower (98.3%). 3 We report a comprehensive investigation of an unexpected case of RMP resistance on Xpert and discuss the implications for patient management.
CASE REPORT
In April 2010, a 49-year-old HIV-infected (CD4 count 169 cells/mm 3 ) male presented to a primary care clinic in Johannesburg, South Africa, with a 6-week history of cough. He had no TB treatment history, but had recently moved from Msinga, KwaZulu-Natal, where an outbreak of extensively drug-resistant TB had occurred in 2006.
An Xpert assay was positive for RMP-resistant Mycobacterium tuberculosis, with ∆Ct Max exceeding 3.5 cycles for probe B ( rst generation software). A repeat Xpert assay indicated RMP-susceptible M. tuberculosis complex (MTC). Anti-tuberculosis treatment and antiretroviral treatment were initiated while awaiting con rmatory results. The patient successfully completed 6 months of rst-line anti-tuberculosis treatment.
The discrepancy in the above results led to a full investigation, for which the patient gave informed consent. Smear microscopy was negative or scanty for acid-fast bacilli, except for induced sputum (Table 1) . Cultures (BACTEC Mycobacteria Growth Indicator Tube 960, BD, Sparks, MD, USA), GenoType ® MTBDRplus (Hain LifeScience GmbH, Nehren, Germany) and Xpert assays were positive for MTC. No assays indicated technical errors. The rst and third Xpert assays indicated RMP resistance, based on a delay in probe B (Ct max 4.9 and 4.1); the second Xpert was RMP-susceptible. MTBDRplus, performed directly on decontaminated sputum to avoid RMP-susceptible
strain overgrowth during culture, showed RMPsusceptible MTC for all three specimens. Phenotypic drug susceptibility testing (indirect proportion method on 7H10 media containing 1.0 μg/ml RMP) also demonstrated RMP susceptibility. DNA sequencing conrmed wild type rpoB sequences in all cultures. 4 Spoligotyping demonstrated an identical spoligotyping pattern (ST4) for all three cultures. 5 An administrative error was considered unlikely, as RMP resistance on Xpert was detected on independent specimens collected on 2 different days. All three cultures shared the same spoligotype pattern (Table 2) , and no drug-resistant TB patient was diagnosed or treated at the clinic at that time. Mixed i nfection with multiple M. tuberculosis strains was unlikely, as spoligotyping demonstrated the absence of a background hybridising pattern and an identical pattern (ST4) in all three isolates. Heteroresistance, i.e., mixed infection with resistant and susceptible populations of the same M. tuberculosis strain, was unlikely, as no growth was observed in any of the RMP-containing plates of isolates 1 and 2 (isolate 3 was contaminated), and careful examination of the DNA sequence chromatogram failed to identify underlying peaks.
DISCUSSION
A false-positive result was the most likely cause of the observed discrepancies, given the wild type rpoB 6 In contrast, Theron et al. identi ed six RMP-resistant cases on Xpert, ve of which were susceptible on phenotypic DST, although ve were genotypically resistant by sequencing and/or MTBDRplus. 7 The complexity of these investigations demonstrates the dif culty in con dently distinguishing false-positive from true-positive RMP-resistant results, particularly in clinical practice.
In response to reports of false-positive RMPr esistant results, the manufacturer performed a root cause analysis, which identi ed the bead manufacturing scale-up and annealing temperature requirements of probe B as potential causes. Solutions include improved bead reconstitution, a software change and adjustment of probe B to increase robustness. 8 The revised assay is being evaluated. While fewer falsepositive results can be expected following assay improvements, an almost perfect (close to 100%) assay speci city will be required before high positive predictive values are achieved in TB suspects in HIV endemic, low MDR-TB prevalence areas. 1, 9 The assay performance has important implications for patient management. The WHO recommends a con rmatory DST in patients with RMP resistance on Xpert. Use of the MTBDRplus assay will lead to a median delay between initial diagnosis and availability of results at the clinic of 40 days, 3 while phenotypic DST will result in even longer delays. 3 These delays give rise to the clinical dilemma of which regimen to start. The WHO recommends MDR-TB treatment in patients diagnosed with RMP resistance on Xpert, but Xpert can be performed at a clinic or microscopy centre, a setting that rarely has access to second-line drugs. Should health care workers start rst-line treatment, or should they defer starting any treatment while awaiting the patient's arrival at the MDR-TB treatment centre? Starting rst-line drugs could pose the risk of ampli cation of resistance to ethambutol or pyrazinamide, 10 limiting future treatment options, while not starting any drugs poses infection control issues and increased risk of death. In patients with low pretest probability living in an area with poor access to MDR-TB treatment, clinicians may reserve the currently limited MDR-TB treatment capacity for those with con rmed MDR-TB or try to balance the risks and bene ts of different regimens based on risk assessment for MDR-TB, type of con rmatory test available ('rapid' MTBDRplus or slower phenotypic DST), ease of access to MDR-TB treatment, nancial burden of referral for MDR-TB treatment (transport cost and loss of employment during hospitalisation), risk of transmission to vulnerable individuals (young children or HIV-positive relatives), patient's HIV status, risk of death while awaiting con rmatory results, risk of toxicity from second-line anti-tuberculosis drugs, and risk of ampli cation of drug resistance.
In conclusion, this report highlights the need for health care workers' understanding of assay performance characteristics when decentralising the diagnosis of drug-resistant TB. These issues should not, however, diminish enthusiasm for the Xpert assay. La Organización Mundial de la Salud aprobó la prueba Xpert ® MTB/RIF (Xpert) en el diagnóstico inicial de las personas con presunción de TB multidrogorresistente (MDR) o de TB asociada con la infección por el virus de la inmunodeficiencia humana (VIH). En el presente artículo se investigó un caso inesperado de resistencia a rifampicina, con el uso de la prueba Xpert: se practicó una repetición de la prueba Xpert, una baciloscopia, la prueba MTBDRplus, el cultivo, las pruebas de sensibilidad a los medicamentos, el espoligotipado y la secuenciación del gen rpoB. Muy probablemente se trató de un resultado positivo falso, dada la secuencia natural del gen rpoB y la exclusión de una infección mixta y de la presencia de poblaciones de micobacterias sensibles y resistentes. Cuando se descentraliza el diagnóstico de la TB resistente a los medicamentos, es importante que los profesionales de salud comprendan las características del mecanismo de la prueba y es preciso contar con un método de confirmación de la resistencia a rifampicina.
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